Kalaris Therapeutics (KLRS) Profit After Tax (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Profit After Tax of -$10.9 million for Q1 2026, down 6.43% year-over-year from -$11.6 million in Q1 2025, and down 8.93% quarter-over-quarter from -$10.0 million in Q4 2025.
Kalaris Therapeutics (KLRS) Profit After Tax (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$10.9 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 6.43% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at -$44.1 million (up 42.0% YoY), while the FY2025 annual figure was -$43.4 million, up 37.25% from the prior year.
- Profit After Tax for Q1 2026 stood at -$10.9 million, down from -$10.0 million in the prior quarter.
- The five-year high for Profit After Tax was -$3.4 million in Q1 2024, with the low at -$59.7 million in Q4 2023.
- The 5-year median for Profit After Tax is -$38.1 million (2024), against an average of -$28.4 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax jumped 91.73% in 2024, then slumped 199.38% in 2025.
- Kalaris Therapeutics' Profit After Tax stood at -$38.1 million in 2022, then tumbled by 56.7% to -$59.7 million in 2023, then jumped by 63.12% to -$22.0 million in 2024, then soared by 54.75% to -$10.0 million in 2025, then decreased by 8.93% to -$10.9 million in 2026.
- Business Quant data shows KLRS's Profit After Tax at -$10.9 million in Q1 2026, -$10.0 million in Q4 2025, and -$11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -11.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.54 Mn |
| Mar 31, 2026 | -10.86 Mn |
| Dec 31, 2025 | -9.97 Mn |
| Sep 30, 2025 | -11.89 Mn |
| Jun 30, 2025 | -11.35 Mn |
| Mar 31, 2025 | -10.20 Mn |
| Dec 31, 2024 | -22.03 Mn |
| Sep 30, 2024 | -38.08 Mn |
| Jun 30, 2024 | -5.65 Mn |
| Mar 31, 2024 | -3.41 Mn |
| Dec 31, 2023 | -59.72 Mn |
| Sep 30, 2023 | -44.27 Mn |
| Jun 30, 2023 | -45.27 Mn |
| Mar 31, 2023 | -41.18 Mn |
| Dec 31, 2022 | -38.11 Mn |
| Sep 30, 2022 | -42.07 Mn |
| Jun 30, 2022 | -44.64 Mn |
| Mar 31, 2022 | -43.86 Mn |
| Dec 31, 2021 | -57.94 Mn |
| Sep 30, 2021 | -45.51 Mn |